WO2002007672A3 - A medicinal aerosol formulation - Google Patents

A medicinal aerosol formulation Download PDF

Info

Publication number
WO2002007672A3
WO2002007672A3 PCT/US2000/042625 US0042625W WO0207672A3 WO 2002007672 A3 WO2002007672 A3 WO 2002007672A3 US 0042625 W US0042625 W US 0042625W WO 0207672 A3 WO0207672 A3 WO 0207672A3
Authority
WO
WIPO (PCT)
Prior art keywords
aerosol formulation
medicinal aerosol
medicinal
particulate
propellant
Prior art date
Application number
PCT/US2000/042625
Other languages
French (fr)
Other versions
WO2002007672A2 (en
Inventor
Akwete L Adjei
Anthony J Cutie
Original Assignee
Aeropharm Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeropharm Technology Inc filed Critical Aeropharm Technology Inc
Priority to AU2001247123A priority Critical patent/AU2001247123A1/en
Publication of WO2002007672A2 publication Critical patent/WO2002007672A2/en
Publication of WO2002007672A3 publication Critical patent/WO2002007672A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Abstract

This invention relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing a particulate drug, or combination of at least two particulate drugs a propellant and a stabilizing agent comprising a water addition.
PCT/US2000/042625 2000-07-19 2000-12-07 A medicinal aerosol formulation WO2002007672A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001247123A AU2001247123A1 (en) 2000-07-19 2000-12-07 A medicinal aerosol formulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61918300A 2000-07-19 2000-07-19
US09/619,183 2000-07-19

Publications (2)

Publication Number Publication Date
WO2002007672A2 WO2002007672A2 (en) 2002-01-31
WO2002007672A3 true WO2002007672A3 (en) 2002-06-27

Family

ID=24480789

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/042625 WO2002007672A2 (en) 2000-07-19 2000-12-07 A medicinal aerosol formulation

Country Status (2)

Country Link
AU (1) AU2001247123A1 (en)
WO (1) WO2002007672A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
WO2004019985A1 (en) * 2002-08-29 2004-03-11 Cipla Ltd Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
EP2327403A3 (en) 2007-02-19 2011-08-31 Cipla Limited Pharmaceutical combinations of at least two bronchodilators
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5676931A (en) * 1993-12-02 1997-10-14 Abbott Laboratories Aerosol drug formulations for use with non CFC propellants
US5695744A (en) * 1992-02-06 1997-12-09 Glaxo Group Limited Medicaments
US6136294A (en) * 1998-09-22 2000-10-24 Aeropharm Technology Inc. Amino acid stabilized medical aerosol formulation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5695744A (en) * 1992-02-06 1997-12-09 Glaxo Group Limited Medicaments
US5676931A (en) * 1993-12-02 1997-10-14 Abbott Laboratories Aerosol drug formulations for use with non CFC propellants
US6136294A (en) * 1998-09-22 2000-10-24 Aeropharm Technology Inc. Amino acid stabilized medical aerosol formulation
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation

Also Published As

Publication number Publication date
AU2001247123A1 (en) 2002-02-05
WO2002007672A2 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
HK1042444A1 (en) A medicinal aerosol formulation
US6136294C1 (en) Amino acid stabilized medical aerosol formulation
CA2416403A1 (en) A medicinal aerosol formulation
CA2497171A1 (en) Water stabilized medicinal aerosol formulation
WO2000041681A3 (en) MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN α-ANTAGONIST
DE60019167D1 (en) PHARMACEUTICAL AEROSOL FORMULATION CONTAINING SALMETEROL AND FLUTICASONE
DE60031504D1 (en) FLUTICASONPROPIONATE DRUG PREPARATION
WO2001082874A3 (en) A medicinal aerosol formulation
MXPA03001752A (en) Pharmaceutical formulation of salmeterol and fluticasone propionate.
WO2002007672A3 (en) A medicinal aerosol formulation
WO2001082868A3 (en) A medicinal aerosol formulation
WO2002000191A3 (en) Bdellosomes
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
WO2001037818A3 (en) Medicament and combination of compatible medicaments
WO2001039741A3 (en) Mitomycin c solution
EP1523976A3 (en) Pharmaceutical formulations of salmeterol
WO2002036105A3 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
WO2002041875A3 (en) Method for producing readily soluble medicament formulations and corresponding formulations
WO2001030372A3 (en) Pharmaceutical agent preparations
CA2446562A1 (en) Pharmaceutical formulation of fluticasone propionate
AU2001262924A1 (en) Flavored product containing medicament or other active agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP